Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.61 |
| ▸ | CES1 | P23141 | 1/20 | 0.61 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | RAF1 | P04049 | 3/20 | 0.43 |
| ▸ | APP | P05067 | 2/20 | 0.43 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
| ▸ | ARAF | P10398 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | MYOC | Q99972 | 1/20 | 0.43 |
| ▸ | DYRK4 | Q9NR20 | 1/20 | 0.43 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.43 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5739845 | 0.79 | CA1 (0.62) | LRRK2MEN1KMT2ACA1CA2 | |
| SCHEMBL5739473 | 0.79 | CA1 (0.62) | LRRK2MAPTMEN1LMNAKMT2A | |
| SCHEMBL20436333 | 0.79 | CA1 (0.62) | LRRK2MAPTMEN1LMNAKMT2A | |
| SCHEMBL12805226 | 0.79 | CA1 (0.62) | LRRK2MEN1KMT2ACA1CA2 | |
| SCHEMBL5740077 | 0.79 | TGM2 (0.61) | TGM2CES1LRRK2MAPTMEN1 | |
| SCHEMBL23647047 | 0.79 | CA1 (0.62) | TGM2CES1LRRK2CA1CA2 | |
| SCHEMBL21999924 | 0.79 | CA1 (0.62) | TGM2CES1LRRK2CA1CA2 | |
| SCHEMBL8912592 | 0.79 | CA1 (0.62) | TGM2CES1LRRK2CA1CA2 | |
| SCHEMBL7791509 | 0.79 | TGM2 (0.77) | TGM2CES1LRRK2MAPTRAF1 | |
| SCHEMBL12235592 | 0.78 | LRRK2 (0.67) | TGM2CES1LRRK2MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644362-A2 | INDOLINONE HYDRAZIDES AS C-MET INHIBITORS | Sugen, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20060009493-A1 | Indolinone hydrazides as c-Met inhibitors | SUGEN, INC. | 2006-01-12 | — | — | US | disclosed |
| WO-2005005378-A2 | INDOLINONE HYDRAZIDES AS C-MET INHIBITORS | SUGEN, INC. (US) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009493-A1 | Indolinone hydrazides as c-Met inhibitors | MET, IGF1R, ROS1 | TGM2 2673/4885CES1 1061/4885LRRK2 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.